Emmaus Life Sciences, Inc.

Total Valuation

Emmaus Life Sciences, Inc. carries a market capitalization of 796,637.00, placing it among publicly traded companies globally. Its enterprise value stands at 32.18M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Emmaus Life Sciences, Inc. currently has 70.19M shares outstanding.

Valuation Ratios

The price-to-sales ratio is 0.08, and the price-to-book ratio stands at 0.00.

Enterprise Valuation

On an enterprise value basis, Emmaus Life Sciences, Inc. trades at an EV/EBITDA multiple of 73.64 and an EV/FCF ratio of 4.36. The EV/Sales ratio of 2.68 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 82.94 provides insight into valuation relative to core operating earnings.

Financial Position

Emmaus Life Sciences, Inc. maintains a current ratio of 0.08, meaning it holds 0.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -47.44, indicating conservative leverage, while an interest coverage ratio of 0.05 demonstrates limited ability to service its debt obligations.

Financial Efficiency

Taxes

Stock Price Statistics

Emmaus Life Sciences, Inc.'s stock has declined approximately -28.25537% over the past 52 weeks. The 50-day moving average sits at 0.01, while the 200-day moving average is 0.01.

Income Statement

Over the trailing twelve months, Emmaus Life Sciences, Inc. generated 12.03M in revenue and converted that into -8.50M in net income, yielding earnings per share of -0.13. EBITDA reached 437,000.00, while operating income came in at 388,000.00.

Balance Sheet

Emmaus Life Sciences, Inc. holds 1.07M in cash and equivalents against 32.19M in total debt, resulting in a net debt position of 29.45M. Total book value stands at -273.40M, with working capital of -64.54M providing operational flexibility.

Cash Flow

Emmaus Life Sciences, Inc. produced -634,000.00 in operating cash flow over the past twelve months. After subtracting -1,000.00 in capital expenditures, free cash flow totaled -635,000.00 - equivalent to -0.01 per share.

Margins

Emmaus Life Sciences, Inc. operates with a gross margin of 93.35, reflecting its pricing power and cost economics. The operating margin of 3.23 and net profit margin of -70.64 provide insight into operational efficiency.

Dividends & Yields

Stock Splits

Emmaus Life Sciences, Inc.'s most recent stock split took place on July 18, 2019 with a 6:1 split ratio.

Scores

Emmaus Life Sciences, Inc. posts an Altman Z-Score of -23.90, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.